340B Drug Pricing Program

Valley Oaks Medical Group Hires New Team of Experts

Retrieved on:

Tuesday, August 16, 2022

Physician, Rheumatology, Neurology, Nephrology, Insurance, Quality of life, Medicare, Patient, 340B Drug Pricing Program, Health insurance, Medical device

Las Vegas, Nevada--(Newsfile Corp. - August 16, 2022) - Valley Oaks Medical Group (Valley Oaks), which provides comprehensive care for senior citizens, has strengthened its management team with the hiring of two key personnel who have deep experience in infusion-based healthcare specialties, such as rheumatology, neurology, oncology, and nephrology.

Key Points:

Las Vegas, Nevada--(Newsfile Corp. - August 16, 2022) - Valley Oaks Medical Group (Valley Oaks), which provides comprehensive care for senior citizens, has strengthened its management team with the hiring of two key personnel who have deep experience in infusion-based healthcare specialties, such as rheumatology, neurology, oncology, and nephrology.
With 1 in 3 Americans affected by rheumatic diseases in the United States, Valley Oaks Medical Group is looking forward to bringing on new rheumatologists.
Valley Oaks Medical Group is dedicated to improving its valued patients' quality of life through compassionate patient management and preventative care.
Valley Oaks wants to refine the way healthcare is administered by keeping patients healthy rather than treating symptoms.

NCPDP Announces Highlights from its 2022 Annual Conference, "BE BOLD. Break Barriers."

Retrieved on:

Thursday, May 5, 2022

SCOTTSDALE, Ariz., May 4, 2022 /PRNewswire-PRWeb/ -- NCPDP announced today highlights from its 2022 Annual Technology & Business Conference, "Be BOLD. Break Barriers." The Annual Conference opened with 20th Surgeon General of the United States, Dr. Jerome Adams' keynote address on a lifetime dedicated to breaking through healthcare, institutional and socioeconomic barriers. Justin Jones-Fosu, world-renowned speaker and author on meaningful work and diversity, inclusion and collaboration, inspired the audience with his keynote address, which included techniques on how to bring meaning to our work and lives, and a workshop on "The Inclusive Mindset." Lygeia Ricciardi, digital health and patient engagement pioneer, shared her perspective on how to empower consumers as partners in their health journey through digital information and tools. Closing featured speaker and conference favorite, Doug Long, returned to deliver his informative IQVIA™ Market Trends Report. Educational track sessions spanned important industry topics such as specialty pharmacy; precision medicine; 340B Drug Pricing Program; NCPDP's Real-Time Prescription Benefit Standard; social determinants of health (SDOH); leveraging big data; legal updates; ePrescribing pet medications, and more.

Key Points:

Highlights Include Newly Elected Board Members, Announcement of Award Recipients, Keynoters and Featured Speakers Headlining the Conference, and State of the Association Report
SCOTTSDALE, Ariz., May 4, 2022 /PRNewswire-PRWeb/ -- NCPDP announced today highlights from its 2022 Annual Technology & Business Conference , "Be BOLD.
Pooja Babbrah, MBA, PBM Practice Lead, Point-of-Care Partners, was appointed Chair of the NCPDP Board of Trustees.
Mara N. Mitchel, Vice President, Pharmacy Programs, Oscar Health, was appointed Vice Chair of the NCPDP Board of Trustees.
For more information about NCPDP Standards, Data Services, Products, Educational Programs and Work Group meetings, go online at http://www.ncpdp.org or call 480.477.1000.

Kalderos releases its 2022 annual report uncovering key drug pricing data gaps that contribute to higher costs for prescription drugs

Retrieved on:

Wednesday, April 13, 2022

Projection, Annual report, Gaps, Data, Machine learning, Patient, Growth, Method, PDF, 340B Drug Pricing Program, Multimedia, Industry, Health, View, Medicaid, Pharmaceutical industry

CHICAGO, April 13, 2022 /PRNewswire/ -- Health tech company Kalderos, maker of a data-driven platform for Drug Discount Management, today released its 2022 annual report, outlining a vision for tech-enabled platform solutions to better serve patients.

Key Points:

In its second year, the Kalderos annual report illuminates how systemic data gaps have undermined efforts to make prescription drugs more affordable and explains why these data gaps challenge every healthcare stakeholder.
"As we rapidly scale our platform for Drug Discount Management, our report highlights the need for accurate data and technological infrastructure to enable collaborative problem-solving."
The Kalderos 2022 annual report identifies a number of challenges that contribute to high drug prices and suggests opportunities to overcome them.
The 2022 Kalderos annual report also uses data to illuminate the variability of an individual drug manufacturer's exposure to noncompliance.

New Drug Channels Institute Study Examines Consolidation and Vertical Integration of U.S. Prescription Market

Retrieved on:

Tuesday, March 15, 2022

PHILADELPHIA, March 15, 2022 /PRNewswire-PRWeb/ --Today, Drug Channels Institute (DCI) released its exclusive, in-depth analysis of U.S. pharmacies and pharmacy benefit managers (PBMs).

Key Points:

PHILADELPHIA, March 15, 2022 /PRNewswire-PRWeb/ --Today, Drug Channels Institute (DCI) released its exclusive, in-depth analysis of U.S. pharmacies and pharmacy benefit managers (PBMs).
"The prescription market has stabilized after the disruptions of the COVID-19 pandemic, although its market structure continues to consolidate and become more vertically integrated," says Drug Channels Institute CEO Adam J. Fein, Ph.D., the study's author and a widely regarded expert on pharmaceutical economics and the drug distribution system.
Drug Channels Institute is a leading source of industry research about pharmaceutical economics and the drug distribution system.
Access Dr. Fein's popular Drug Channels blog at http://www.drugchannels.net .

AHF: Biden Chides Drug Industry, Urges Enforcement of 340B Statute

Retrieved on:

Friday, February 11, 2022

AIDS Healthcare Foundation ( AHF ) welcomed U.S. President Joe Bidens remarks chiding the drug industry and defending the 340B drug pricing program .

Key Points:

AIDS Healthcare Foundation ( AHF ) welcomed U.S. President Joe Bidens remarks chiding the drug industry and defending the 340B drug pricing program .
The 340B Drug Pricing Program is a U.S. government program that requires drug companies to provide drugs to eligible nonprofit, safety net organizations at a discount.
Because they have violated the law, the U.S. Health Resources Services Administration (HRSA) has taken action against drug companies for their illegal refusal to offer 340B discounts to 340B covered entities.
As many as 13 drug companies have refused to comply with HRSAs demands to obey the law and resume offering 340B pricing to contract pharmacies.

Amneal to Virtually Participate at Upcoming Investor Conferences

Retrieved on:

Friday, November 12, 2021

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products.

Key Points:

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products.
The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.
Amneal has an extensive portfolio of approximately 250 product families and is expanding its portfolio to include complex dosage forms, including biosimilars, in a broad range of therapeutic areas.
The Company also markets a portfolio of branded pharmaceutical products through its Specialty segment focused principally on central nervous system and endocrine disorders.

Amneal Launches Generic Dexamethasone Following ANDA Approval by FDA

Retrieved on:

Wednesday, October 27, 2021

Research, Infectious Diseases, FDA, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Vitamin, Infection, Medication, Research, Dexamethasone, Defense, Plasma protein binding, Tablet, Munitions Safety Information Analysis Center, Common stock, Security (finance), U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, FDA, NYSE, Food, United States Department of Veterans Affairs, 340B Drug Pricing Program, Degenerative disease, Risk, Regulation of tobacco by the U.S. Food and Drug Administration, Department of Defense Architecture Framework, Annual report, Forward-looking statement, Veterans' affairs, Company, Investment, Potassium, COVID-19, Growth, HPA, Packager, Central nervous system, Ownership, Department, Abbreviated New Drug Application, Sodium, ANDA, Pharmaceutical industry, Risk management

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced that it is launching dexamethasone, 4mg and 6 mg, following Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA).

Key Points:

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced that it is launching dexamethasone, 4mg and 6 mg, following Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA).
Dexamethasone, the generic version of Decadron, is a well-established anti-inflammatory glucocorticoid steroid used to treat several medical conditions, including respiratory complications associated with COVID-19.
Todays approval and launch of dexamethasone reflects the continued execution of our innovation agenda.
Dexamethasone tablets can produce reversible hypothalamic-pituitary adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency.

Community Access National Network Releases Policy Report on 340 Drug Pricing Program

Retrieved on:

Tuesday, October 19, 2021

Drug, 340B Drug Pricing Program, Congress, Patient, Health insurance

The idea was brilliantly simple; drug manufacturers could have a guaranteed income from participation in the Medicaid program, and "covered entities" could have guaranteed access to discounted medications.

Key Points:

The idea was brilliantly simple; drug manufacturers could have a guaranteed income from participation in the Medicaid program, and "covered entities" could have guaranteed access to discounted medications.
This payment program is little known but, now it is significantly large.
It is the 340B Drug Pricing Program .
Read more on the Community Access National Network Website: https://www.hiv-hcv-watch.com/blog/340b-1

Amneal to Report Third Quarter 2021 Results on November 3, 2021

Retrieved on:

Wednesday, October 6, 2021

Health, Pharmaceutical, 340B Drug Pricing Program, Patient, Defense, Degenerative disease, Medication, Central nervous system, Company, United States Department of Veterans Affairs, Veterans' affairs, Vitamin, Packager, NYSE, Amneal Pharmaceuticals, Department of Defense Architecture Framework, Department, Internet service provider, Pharmaceutical industry

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2021 financial results on Wednesday, November 3, 2021, prior to market open.

Key Points:

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2021 financial results on Wednesday, November 3, 2021, prior to market open.
The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on November 3, 2021.
To access the call through a conference line, dial (844) 200-6205 (in the U.S.) or (929) 526-1599 (international callers).
A replay of the conference call will be posted shortly after the call and will be available for seven days.

Amneal to Virtually Participate at Morgan Stanley 19th Annual Global Healthcare Conference

Retrieved on:

Tuesday, September 7, 2021

Pharmaceutical, Medical Supplies, Public Relations, Investor Relations, General Health, Health, Medical Devices, Communications, Other Health

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the Company) today announced that members of management will participate at the Morgan Stanley Global Healthcare Conference held on September 15, 2021.

Key Points:

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the Company) today announced that members of management will participate at the Morgan Stanley Global Healthcare Conference held on September 15, 2021.
A replay of the webcast will be posted shortly after the call and will be available for 90 days following the event.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products.
The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.